Metagenomi Therapeutics (MGX) News
NASDAQ: MGXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MGX news summary
We found 4 recent headlines mentioning Metagenomi Therapeutics (MGX): 0 in the past week and 3 in the past 30 days, most often from GlobeNewswire. MGX is making an outsized move today, down 7.95% at $0.565, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in London", was published by GlobeNewswire on Nov 11, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Metagenomi Therapeutics headlines
- Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in LondonEMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to…GlobeNewswire
- Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial ResultsFDA clearance enables initiation of a first-in-human Phase 1/2 trial of MGX-001 in patients with hemophilia AGlobeNewswire
- Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual MeetingMGX-001 data establish preclinical proof-of-concept in hemophilia A On track to initiate global clinical trial in 2027GlobeNewswire
- Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare ConferenceEMERYVILLE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to…GlobeNewswire